Upgrade your membership to see all of the expert analysis we have published on PRAH now!
Abrupt Retreat Amid Broadly Weak Market Conditions - Monday, December 17, 2018
P R A Health Sciences (PRAH -$3.51 or -3.52% to 96.21) recently undercut its pivot point after a noted "negative reversal" at its high raised concerns. It made quick headway after highlighted in yellow with pivot point cited based on its 9/14/18 high plus 10 cents in the 11/30/18 mid-day report (read here). Then just as quickly it abruptly retreated, violating its 50-day and 200-day moving average (DMA) lines. It was last shown in this FSU section on 11/30/18 with an annotated graph under the headline, "Streak of Gains For New Highs Marked by Increasing Volume".Technically, it triggered a technical buy signal on 11/29/18 with a gain backed by +103% above average volume. However, new buying efforts in stocks, since October 10th, were mostly discouraged under the fact-based investment system due to to weak market (M criteria) repeatedly noted.
Recently it reported earnings +28% on +23% sales revenues for the Sep '18 quarter, its 6th consecutive quarterly comparison above the +25% minimum earnings guideline (C criteria). Its annual earnings (A criteria) history has been strong and it has earned a 92 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 533 in Dec '17 to 637 in Sep '18. Its current Up/Down Volume Ratio of 0.9 is an unbiased indication its shares have been under slight distributional pressure over the past 50 days. It has a Timeliness rating of A and Sponsorship Rating of B. It completed yet another Secondary Offering on 8/07/18, and prior Secondary Offerings on 8/09/17, 3/04/16, 5/04/16, and 11/15/16.
Charts courtesy of www.stockcharts.com
Streak of Gains For New Highs Marked by Increasing Volume - Friday, November 30, 2018
P R A Health Sciences (PRAH +$2.86 or +2.51% to $116.74) was highlighted in yellow with pivot point cited based on its 9/14/18 high plus 10 cents in the earlier mid-day report (read here). Technically, it triggered a technical buy signal on the prior session with a gain backed by +103% above average volume. However, new buying efforts in all stocks are discouraged under the fact-based investment system until a new confirmed market rally (M criteria) is noted. It hit a new 52-week high with above average volume behind today's 8th consecutive gain, rallying straight up from is 200-day moving average (DMA) line.Recently it reported earnings +28% on +23% sales revenues for the Sep '18 quarter, its 6th consecutive quarterly comparison above the +25% minimum earnings guideline (C criteria). Its annual earnings (A criteria) history has been strong and it has earned a 92 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 533 in Dec '17 to 627 in Sep '18. Its current Up/Down Volume Ratio of 1.2 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness rating of A and Sponsorship Rating of B. It completed yet another Secondary Offering on 8/07/18, and prior Secondary Offerings on 8/09/17, 3/04/16, 5/04/16, and 11/15/16.
Charts courtesy of www.stockcharts.com